Fabry Disease Market - Risk Factors, Comorbidities/Manifestations, Epidemiological Trends and Fabry Disease Forecasts to 2024 in New Research Report

PUNE, India, September 7, 2015 /PRNewswire/ --

The EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024 forecasts that diagnosed prevalent cases of Fabry disease in the 7MM will increase to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.71% during the forecast period.

Complete report on fabry disease market spread across 30 pages, talking about age and sex specific diagnosed prevalent cases and supported with 4 tables and 3 figures is now available at http://www.reportsnreports.com/reports/421367-epicast-report-fabry-disease-epidemiology-forecast-to-2024.html .

Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of Fabry disease, with 3,540 diagnosed prevalent cases, whereas Spain will have the lowest number, with 523 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of Fabry disease in 2024, with 819 diagnosed prevalent cases, and Spain will have the least number, with 523 diagnosed prevalent cases. Japan will have the highest AGR at 8.16%, while Germany will have the lowest AGR at 6.48%.

This report provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex. To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in the 7MM, Epidemiologists used data available from Fabry Support & Information Group (FSIG) for the US and the EU markets, and the data available for Japan from a population-based study conducted in Japan along with data available from FSIG for Asia-Pacific.

Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008). The organ dysfunction is regarded as the first clinical evidence of Fabry disease (Tsuboi et al., 2012). The symptoms of Fabry disease are typically severe in men, whereas women show variable range of symptoms with some being non symptomatic and others showing severe symptoms (Golfomitsos et al., 2012). Order a copy of EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024 at http://www.reportsnreports.com/Purchase.aspx?name=421367 .

The fabry disease market EpiCast report provides an overview of the risk factors, comorbidities, and global trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of Fabry disease segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and comorbidities in these markets. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM. The research aims to help develop business strategies by understanding the trends shaping and driving the global Fabry disease market. Quantify patient populations in the global Fabry disease market to improve product design, pricing, and launch plans as well as organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Fabry disease therapeutics in each of the markets covered.

On a related note, the Fabry Disease - Pipeline Review, H1 2015 market research report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. Companies like Amicus Therapeutics, Inc., Biosidus S.A., Genzyme Corporation, greenovation Biotech GmbH, iBio, Inc., ISU ABXIS Co. Ltd., JCR Pharmaceuticals Co., Ltd., Neuraltus Pharmaceuticals, Inc., Pharming Group N.V., Protalix BioTherapeutics, Inc. and Synageva BioPharma Corp. are discussed in the research. Also included are drug profiles for (migalastat hydrochloride + agalsidase alfa), agalsidase alfa, agalsidase beta biosimilar, Alpha-Galactosidase, Genz-682452, GZ-402671, JR-051, migalastat hydrochloride, Next Generation biologics for Pompe, Fabry and Hunter, NP-003, PRX-102 and Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease. Comprehensive table of contents and more on this fabry disease market pipeline review report is available at http://www.reportsnreports.com/reports/345693-fabry-disease-pipeline-review-h1-2015.html .

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:  

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]